As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Esperion Therapeutics, Inc. The largest reported stake is Glazer Capital, LLC's, at 8.15%. 9 filings are on record since August 13, 2025 (Schedule 13G, June 8, 2026).
Sell to companies like Esperion Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: The Goldman Sachs Group, Inc. · Sole voting: 0 · Shared voting: 17,216,493 · Sole dispositive: 0 · Shared dispositive: 17,216,538 · SCHEDULE 13G, 2026-08-13
- · Reporting person: Vanguard Capital Management · Sole voting: 1,677,667 · Shared voting: 0 · Sole dispositive: 13,105,104 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-31
- · Reporting person: Wasatch Advisors LP · Sole voting: 1,930,185 · Shared voting: 0 · Sole dispositive: 1,930,185 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-14
- · Reporting person: Glazer Capital, LLC · Sole voting: 0 · Shared voting: 20,975,620 · Sole dispositive: 0 · Shared dispositive: 20,975,620 · SCHEDULE 13G, 2026-06-08
- · Holder: Wasatch Advisors LP · Percent: 6.1% · SCHEDULE 13G
Esperion Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-13. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Glazer Capital, LLC | 8.15% | 20,975,620 | SCHEDULE 13G, 2026-06-08 | 2026-06-01 |
| The Goldman Sachs Group, Inc. | 6.7% | 17,222,156 | SCHEDULE 13G, 2026-08-13 | 2026-06-30 |
| Vanguard Capital Management | 5.08% | 13,105,104 | SCHEDULE 13G, 2026-07-31 | 2026-06-30 |
| Two Seas Capital LP | 4.7% | 9,749,724 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Wasatch Advisors LP | 0.7% | 1,930,185 | SCHEDULE 13G/A, 2026-07-14 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Esperion Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Esperion Therapeutics, Inc. and the records around it.
Esperion Therapeutics, Inc. elsewhere on the record
- Acquisition Jul 2026
Companies that share a holder
- Two Seas Capital LP also filed stake reports on 14 other companies: NEKTAR THERAPEUTICS (Sep 2026), Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026)
- Wasatch Advisors LP also filed stake reports on 72 other companies: Smith Douglas Homes Corp (Oct 2026), Amtech Systems Inc (Oct 2026), BBB Foods Inc (Oct 2026)
- Glazer Capital, LLC also filed stake reports on 107 other companies: Bumble Inc (Oct 2026), Weave Communications Inc (Oct 2026), Utz Brands Inc (Oct 2026)
Watch Esperion Therapeutics, Inc.
Get an email when Esperion Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Esperion Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Esperion Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Esperion Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Glazer Capital, LLC | 0 | 20,975,620 | 0 | 20,975,620 | SCHEDULE 13G, 2026-06-08 |
| Paul J. Glazer | 0 | 20,975,620 | 0 | 20,975,620 | SCHEDULE 13G, 2026-06-08 |
| The Goldman Sachs Group, Inc. | 0 | 17,216,493 | 0 | 17,216,538 | SCHEDULE 13G, 2026-08-13 |
| Goldman Sachs & Co. LLC | 0 | 17,216,493 | 0 | 17,216,538 | SCHEDULE 13G, 2026-08-13 |
| Vanguard Capital Management | 1,677,667 | 0 | 13,105,104 | 0 | SCHEDULE 13G, 2026-07-31 |
| Wasatch Advisors LP | 1,930,185 | 0 | 1,930,185 | 0 | SCHEDULE 13G/A, 2026-07-14 |
The latest filing identifies Esperion Therapeutics, Inc. by CUSIP 29664W105 and gives its principal executive office as 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR (SCHEDULE 13G, 2026-08-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Two Seas Capital LP | 5% | SCHEDULE 13G |
| 2025-11-12 | Wasatch Advisors LP | 3.5% | SCHEDULE 13G/A |
| 2025-11-14 | Two Seas Capital LP | 4.7% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-22 | Wasatch Advisors LP | 6.1% | SCHEDULE 13G |
| 2026-06-08 | Glazer Capital, LLC | 8.15% | SCHEDULE 13G |
| 2026-07-14 | Wasatch Advisors LP | 0.7% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Capital Management | 5.08% | SCHEDULE 13G |
| 2026-08-13 | The Goldman Sachs Group, Inc. | 6.7% | SCHEDULE 13G |
Questions about who owns Esperion Therapeutics, Inc.
Who owns Esperion Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Esperion Therapeutics, Inc.: Glazer Capital, LLC (8.15%, Schedule 13G, filed 2026-06-08), The Goldman Sachs Group, Inc. (6.7%, Schedule 13G, filed 2026-08-13) and Vanguard Capital Management (5.08%, Schedule 13G, filed 2026-07-31).
Who are the largest shareholders of Esperion Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Esperion Therapeutics, Inc. on this page are Glazer Capital, LLC (8.15%), The Goldman Sachs Group, Inc. (6.7%) and Vanguard Capital Management (5.08%).
When did Glazer Capital, LLC buy into Esperion Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Glazer Capital, LLC on this page is the Schedule 13G, filed 2026-06-08, reporting 8.15%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Esperion Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 13, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 1, 2026 | Acquired by Essence Parent Inc. | $100M | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for Esperion Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.